CoChat
Sign Up
Cited by 29Down syndrome and intellectual disability researchDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS): A 10‐year report

Open access
Handen, Benjamin L., Mapstone, Mark, Hartley, Sigan, Andrews, Howard, Christian, Brad, Lee, Joseph H., Tudorascu, Dana, Hom, Christy +18 more·2025·Alzheimer's & Dementia
DOI 10.1002/alz.70294PMC PMC12079517
Open this paper in CoChat — free accountOpen PDF

Abstract

INTRODUCTION: Virtually all adults with Down syndrome (DS) will accumulate the neuropathologies associated with Alzheimer's disease (AD) by age 40, with the majority having a clinical dementia diagnosis by their middle 50s. METHODS: This paper complements a 2020 publication describing the Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS) methodology by highlighting protocol changes since initial funding in 2015. It describes available clinical, neuropsychological, neuroimaging, and biofluid data and bio‐specimen repository. Ten years of accomplishments are summarized. RESULTS: Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow‐up visits. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. DISCUSSION: ABC‐DS is the largest U.S.‐based, multi‐site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD. Highlights: The Alzheimer's Biomarker Consortium—Down Syndrome (ABC‐DS) is entering its 10th year. Over 500 adults with Down syndrome (DS) and 59 sibling controls have been enrolled. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted. Multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. It is positioned to continue to make substantial contributions to the DS field.

AI snapshot

Written from the paper’s full text.

TL;DR

ABC‐DS is the largest U.S.‐based, multi‐site longitudinal biomarker initiative targeting Alzheimer’s disease in adults with Down syndrome, now reporting 10 years of enrollment and data collection. Since 2015 it has enrolled over 500 adults with DS and 59 sibling controls, generating extensive clinical, imaging, omics, and biospecimen resources for external investigators.

Key findings

  • Over 500 adults with DS and 59 sibling controls have enrolled since 2015, with nearly 800 follow‐up visits; more than 900 MRI, 800 amyloid PET, and 600 tau PET scans have been conducted, and omics data have been generated from over 1100 blood and 100 CSF samples.
  • At baseline as of 9/15/23, among 503 participants with DS, 369 (73%) were cognitively stable, 59 (12%) had MCI‐DS, 54 (11%) had dementia, and 21 (4%) were undetermined; all 59 sibling controls were cognitively stable.
  • Among 346 participants with DS who completed at least one follow‐up visit, 16.11% (n = 39) progressed from cognitively stable to MCI and 18.02% (n = 53) progressed from cognitively stable to AD or from MCI to AD.
  • As of February 27, 2025, ABC‐DS had received 412 data requests, 192 (46.6%) from external investigators, and had produced over 200 peer‐reviewed papers, a book, 10 book chapters, and hundreds of conference presentations.

Methods

  • Multi‐site, multi‐cohort longitudinal study of adults with DS (ages 25+) and a small number of healthy neurotypical sibling controls, with in‐person visits at baseline and approximately every 16 months.
  • Assessments include physical/neurological examination, cognitive battery, informant/caregiver questionnaires, MRI and PET scans (amyloid, tau, FDG), peripheral blood draw, optional lumbar puncture for CSF, and a brain donation program.
  • This 10‐year report summarizes protocol changes since 2015 and available data through “Freeze 4” (September 15, 2023), including enrollment, data corpus, biospecimen availability, and productivity; no new primary statistical analysis is reported.

Limitations

  • The paper states challenges including combining ABC‐DS 2015 and 2020 data into a seamless database, addressing scanner/software/pipeline upgrades, rapidly integrating new sites, prioritizing emerging fluid biomarkers given finite biospecimens and funding, and ensuring inclusion of underserved groups and rural areas.
  • Evident from the reported baseline table: the DS cohort was 91% White, 1% Black, and 5% Hispanic, and sibling controls were 100% White, limiting generalizability despite stated efforts to improve diversity.
  • Evident from the reported data: CSF collection was optional and small (100 DS samples, 7 sibling samples), and carry‐over participants had no inclusion/exclusion criteria, which may affect cohort composition and longitudinal comparability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/alz.70294

Cites

56 of 57 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

2 of 11 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    DS-AD is likely the single greatest impediment to extending life expectancy of adults with Down syndrome beyond their 60s.

    “DS‐AD is likely the single greatest impediment to extending life expectancy of adults with DS beyond their 60s. 7”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [7] Iulita MF, Garzón Chavez D, Klitgaard Christensen M, et al. Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Netw Open. 2022; 5. PMC9127560 35604690 source
  • Premisecitation

    The Down syndrome population has generally been excluded from research on sporadic Alzheimer's disease.

    “While significant gains have been made during the past 20–30 years toward increasing understanding of the causes, risk factors, and potential treatment of sporadic AD, the DS population has generally been excluded from this work. 8”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [8] Rafii MS, Fortea J. Down Syndrome in a New Era for Alzheimer Disease. JAMA. 2023; 330: 2157‐ 2158. 37991807 PMC11324235 source

      In “Down Syndrome in a New Era for Alzheimer Disease” (page unavailable), the paper says adults with Down syndrome were not included in the large trials of recently approved Alzheimer disease treatments and that few Alzheimer disease trials have included them. That supports exclusion from treatment trials, but not the broader claim that they were generally excluded from 20–30 years of research into sporadic Alzheimer disease’s causes and risk factors; the paper also describes recent Down syndrome biomarker studies. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • Findingown data

    More than 800 amyloid positron emission tomography (PET) scans have been conducted in ABC-DS.

    “More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples.”
    Quote in the paperNot a substantial claim
  • Findingown data

    Of the 503 participants with Down syndrome enrolled in the 2015 and/or 2020 ABC-DS studies, 59 (11.7%) were diagnosed with mild cognitive impairment at baseline.

    “Of the 503 participants with DS enrolled in the 2015 and/or 2020 ABC‐DS studies, 59 (11.7%) were diagnosed with MCI and 54 (10.7%) were diagnosed with AD at baseline (note that individuals with MCI or AD were included in ABC‐DS 2015).”
    Quote in the paperNot a substantial claim
  • Findingown data

    Nearly 800 follow-up visits have occurred in ABC-DS since 2015.

    “Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow‐up visits.”
    Quote in the paperNot a substantial claim
  • Classified as probably not a substantial claim. 30
  • May combine two claims. 11
  • The quote only partly states this claim. 1

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    The primary biomarkers of interest have remained fairly consistent since ABC-DS began.

    “The primary biomarkers of interest have remained fairly consistent since ABC‐DS began.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingnone given

    Since its inception in 2015, ABC-DS has undergone four data locks, with the most recent occurring on September 15, 2023.

    “Since its inception in 2015, ABC‐DS has undergone four data locks, with the most recent occurring in September 15, 2023.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    ABC-DS is entering its 10th year.

    “The Alzheimer's Biomarker Consortium—Down Syndrome (ABC‐DS) is entering its 10th year.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    ABC-DS data has served as the basis for two NIH-funded F training awards.

    “two F training awards”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    During the past 10 years, dozens of doctoral and post-doctoral students have been supported in fields including genetics, biostatistics, psychology, neuroimaging, and neuropathology through ABC-DS.

    “During the past 10 years, dozens of doctoral and post‐doctoral students have been supported in fields including genetics, biostatistics, psychology, neuroimaging, and neuropathology through ABC‐DS.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data

    13 ABC-DS participants have died to date, mostly due to complications associated with Alzheimer's disease.

    “Among the reasons that participants have been lost to follow‐up include death (13 to date, mostly due to complications associated with AD), site closure (for participants from the Banner Institute), and illness (e.g., advanced dementia, medical issues).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    ABC-DS investigators have been able to leverage ABC-DS resources and data to successfully obtain NIH funding for related investigations, including "Lifestyle and Alzheimer's disease in Down syndrome" (PI Hartley, R01 AG070028), "Cerebrovascular contributions to Alzheimer's disease in adults with Down syndrome" (MPI Brickman/Head, RF1AG079519), and "Heterogeneous genetics effects and mediation in阿尔

    “ABC‐DS investigators have also been able to leverage ABC‐DS resources and data to successfully obtain NIH funding for related investigations, including “Lifestyle and Alzheimer's disease in Down syndrome” (PI Hartley, R01 AG070028), “Cerebrovascular contributions to Alzheimer's disease in adults with Down syndrome” (MPI Brickman/Head, RF1AG079519), and “Heterogeneous genetics effects and mediation”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    ABC-DS data has served as the basis for three NIH-funded K training awards.

    “ABC‐DS data has served as the basis for three NIH‐funded K training awards”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

    Findingnone given

    ABC-DS data has served as the basis for an Alzheimer's Association Research Fellowship to Promote Diversity, a Jerome Lejeune Foundation grant, and a Brightfocus Foundation Grant.

    “an Alzheimer's Association Research Fellowship to Promote Diversity (23AARFD‐1022715; Awardee: Aguilar; Mentor: Head), a Jerome Lejeune Foundation grant (Awardee: Aguilar; Mentor: Head), and a Brightfocus Foundation Grant (BFF A2022021F; Awardee: Sordo; Mentor: Head).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingnone given

    Currently (as of February 27, 2025) over 200 peer-reviewed research papers, a book, 10 book chapters, and hundreds of conference presentations and posters have been published or presented using ABC-DS data.

    “Currently (as of February 27, 2025) over 200 peer‐reviewed research papers (including a 2020 special issue of Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring), a book, 10 book chapters, and hundreds of conference presentations and posters have been published or presented using ABC‐DS data.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims. The quote only partly states this claim.

    Findingown data

    To date (as of February 27, 2025), there have been 412 data requests, of which 192 (46.6%) were from external investigators.

    “To date (as of February 27, 2025), there have been 412 data requests, of which 192 (46.6%)”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    APOE genotype data are available for all study participants.

    “APOE genotype data are available for all study participants.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    A quarter of ABC-DS participants who underwent a lumbar puncture returned for at least one follow-up LP as of the writing of the manuscript.

    “As anticipated, only a small number of participants agreed to undergo an LP procedure for the collection of CSF; a quarter of this group returned for at least one follow‐up LP as of the writing of this manuscript.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Two supplements in 2019 and 2023 provided the funding to include additional clinical performance sites (Washington University and University of Kansas Medical Center) to the Consortium.

    “Two supplements in 2019 and 2023 provided the funding to include additional clinical performance sites (Washington University and University of Kansas Medical Center) to the Consortium”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Since 2015, ABC-DS investigators have been awarded over a dozen administrative supplements to provide additional support to the Consortium.

    “In addition, since 2015, ABC‐DS investigators have been awarded over a dozen administrative supplements to provide additional support to the Consortium.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    Four administrative supplements allowed for the expansion of the ABC-DS protocol.

    “four administrative supplements allowed for the expansion of the ABC‐DS protocol”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingnone given

    As individuals with Down syndrome developed more significant Alzheimer's disease symptoms, travel to study sites could be challenging and administration of cognitive assessments more difficult.

    “In addition, as individuals with DS developed more significant AD symptoms, travel to study sites could be challenging, and administration of cognitive assessments more difficult.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Of the nine approved bio-sample requests, five have been from investigators outside of ABC-DS.

    “Of the nine approved bio‐sample requests, five have been from investigators outside of ABC‐DS.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Only a small number of ABC-DS participants agreed to undergo a lumbar puncture for CSF collection.

    “As anticipated, only a small number of participants agreed to undergo an LP procedure for the collection of CSF; a quarter of this group returned for at least one follow‐up LP as of the writing of this manuscript.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingnone given

    During the COVID-19 pandemic (2020-2022), many in-person ABC-DS visits could not be scheduled and only study partner data was obtained.

    “It should be noted that during the coronavirus disease 2019 (COVID‐19) pandemic (2020–2022), many of the in‐person visits could not be scheduled and only study partner data was obtained.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    12 ABC-DS participants have provided brain donations.

    “Although not a requirement for participation in ABC‐DS, 12 participants have provided brain donations.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    Clinical classifications in ABC-DS are based on individual consensus conferences involving expert DS clinicians, study coordinators, and highly trained staff familiar with each participant.

    “Clinical classifications are based on individual consensus conferences involving expert DS clinicians, study coordinators, and highly trained and experienced staff who are familiar with each participant.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    ABC-DS is the largest U.S.-based, multi-site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with Down syndrome at risk for Alzheimer's disease.

    “ABC‐DS is the largest U.S.‐based, multi‐site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    The scanning procedures in ABC-DS are generally well-tolerated, and sedation is never used.

    “The scanning procedures are generally well‐tolerated, and sedation is never used.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    A brain donation program is in place in ABC-DS that allows researchers to connect in vivo clinical and cognitive data, omics, and neuroimaging measures with histopathology and other post mortem outcomes in a clinicopathological framework.

    “Finally, a brain donation program is in place which allows researchers to connect in vivo clinical and cognitive data, omics, and neuroimaging measures with histopathology and other post mortem outcomes in a clinicopathological framework.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationreasoning

    Without a more detailed characterization of known and novel biomarkers, personalization of prognosis and diagnosis for DS-AD will falter.

    “Although the outcome of these aims is beginning to inform models that can predict the trajectory of the disease and its clinical manifestations at the individual level of this genetic form of AD, without a more detailed characterization of known and novel biomarkers, personalization of prognosis and diagnosis will falter.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    The ABC-DS consensus conference team is blind to neuroimaging, genetics, and omics data for participants discussed, but has access to clinical blood lab panel results.

    “This team is blind to neuroimaging, genetics, and omics data for participants discussed at conference but has access to clinical blood lab panel results (e.g., thyroid stimulating hormone [TSH], glucose, and cholesterol levels).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    The ABC-DS consortium has already had a significant impact on the design and selection of assessment tools to be used in many Alzheimer's disease prevention trials for the Down syndrome population.

    “The consortium has already had a significant impact on the design and selection of assessment tools to be used in many of the Alzheimer's disease (AD) prevention trials for the DS population.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    There are currently close to a quarter of a million individuals with Down syndrome in the United States and over five million worldwide.

    “There are currently close to a quarter of a million individuals with DS in the United States alone and over five million world‐wide. 11”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [11] de Graaf G, Buckley F, Skotko B. People living with Down syndrome in the USA: BIRTHS AND POPULATION. In: Population DS, editor.2024.

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    All data collected in ABC-DS are made available, without embargo, to qualified outside investigators through the NIH-sponsored data repositories at LONI at the University of Southern California.

    “Finally, all data collected in the study are made available, without embargo, to qualified outside investigators through the NIH‐sponsored data repositories at LONI at the University of Southern California.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    Data in ABC-DS are locked every 16-24 months and, after rigorous quality assurance and quality control procedures, are hosted on the LONI platform.

    “Data are locked every 16–24 months, and after rigorous quality assurance and quality control procedures, are hosted on the LONI platform.”
    Quote in the paperNot a substantial claim
31 of 31

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Genome-wide microarray participant counts do not add up

    Minor

    The stated 375 adults with DS and 59 sibling controls total 434 participants, not 418.

    Reported 418 · recomputed 434

  • Tau PET total is 600, not more than 600

    Minor

    The table lists 524 tau PET scans for participants with DS and 76 for sibling controls, totaling exactly 600. The abstract says more than 600 were conducted.

  • Kansas site has conflicting joining years

    Minor

    The narrative says the University of Kansas Medical Center was added in 2024, whereas Table 1 lists its joining year as 2023.

  • Puerto Rico site has conflicting joining years

    Minor

    The narrative says the University of Puerto Rico was added in 2025, whereas Table 1 lists its joining year as 2024.

  • September 2023 is called the most recent data freeze despite a 2024 freeze

    Minor

    The paper identifies Freeze 5 in fall 2024 as the latest data freeze, then calls the September 2023 freeze the most recent one.

5 of 5

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. Eurlings H, 2006, Dementia Questionnaire for People with Learning Disabilities (DLD)
  2. Korkman M, 2007, NEPSY—Second Edition (NEPSY‐II)
  3. Wechsler D, 2003, Wechsler Intelligence Scale for Children‐Fourth Edition: Administration and Scoring Manual
  4. Reiss S, 1994, Reiss Screen for Maladaptive Behavior

Cited by

Sorted by citations

Related

Authors
Handen, B. L., Mapstone, M., Hartley, S., Andrews, H., Christian, B., Lee, J. H., Tudorascu, D., Hom, C., Ances, B. M., Zaman, S., Krinsky‐McHale, S., Brickman, A. M., Rosas, H. D., Cohen, A., Petersen, M., O'Bryant, S., Harp, J. P., Schmitt, F., Ptomey, L., Burns, J., Lott, I. T., Lai, F., Silverman, W., Laymon, C., Head, E., & the Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS)
Affiliations
  • University of Pittsburgh (US)
  • University of California, Irvine (US)
  • University of Wisconsin–Madison (US)
  • Columbia University Irving Medical Center (US)
  • Columbia University (US)
  • Washington University in St. Louis (US)
  • University of Cambridge (GB)
  • NYS Institute for Basic Research in Developmental Disabilities Department of Psychology Staten Island New York USA
  • Harvard University (US)
  • University of North Texas Health Science Center (US)
  • University of North Texas Health Science Center Department of Family Medicine Fort Worth Texas USA
  • University of Kentucky (US)
  • University of Kansas Medical Center (US)
Corresponding author
Handen, Benjamin L.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2025-05
Volume
21
Issue
5
Pages
e70294-e70294
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.70294
PMC
PMC12079517
OpenAlex
W4410410539
Semantic Scholar
b22fd10b811da8a24e35e1a26679c0616fc18b96
Cited by
29
References
55
Citations by year
2026: 24 · 2025: 5
FWCI
23.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
Funders
National Institute on Aging (U19AG068054, U01AG051406, U01AG051412)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
Down syndrome, Alzheimer's disease
MeSH terms
Adult, Alzheimer Disease, Brain, Down Syndrome, Female, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Biomarkers, tau Proteins, Positron-Emission Tomography, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-19.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-19.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review